Main Article Content

Muhammad Adnan
Muhammad Naeem Khan
Rizwan Ali
Zafran Ullah
Ihtisham Ahmed
Syed Muhammad Salman


World health organization, Limit of Detection, Limit of Quantification, International Commission for Harmonization, High Performance Liquid Chromatography.


A fixed-dose amalgamation pill having linagliptin and empagliflozin, which includes a sodium-glucose co-transporter 2 (SGLT2) inhibitor as well as a dipeptidyl peptidase 4 (DPP-4) inhibitor correspondingly, has gained approval recently. This study presents a developed RP-HPLC technique for measuring Empagliflozin and Linagliptin in pharmaceutical preparations. The analytical method has validated for key characteristics, including linearity, precision, robustness, and accuracy, in accordance with the rules set by the ICH. The RP-HPLC analysis performed using an ODS column with measurements of 250 mm in length and 4.6 mm in diameter, and a 5 µm particle size. The mobile phase consisted of an ammonium acetate buffer (0.770 g per 1000 mL) as well as acetonitrile in a 65:35 (v/v) ratio, with a flow rate set at 1.00 mL/min. The detection has been carried out using a PDA detector. The optimal detection wavelengths were determined to be 210 nm for Empagliflozin and 290 nm for Linagliptin. For Empagliflozin, the calibration curve demonstrated tremendous linearity within the range of conc. for 20-120 µg/mL, having outstanding regression coefficient (R² = 0.9999). Similarly, Linagliptin exhibited linearity over a conc. range of 4.0 to 24 µg/mL, also having a regression coefficient of 0.9999. Limits of detection (LODs) for Linagliptin as well as Empagliflozin has proven at 0.313 µg/mL and 1.48 µg/mL, respectively. LOQs were discovered to be 4.48 µg/mL for Empagliflozin and 0.949 µg/mL for Linagliptin. Accuracy of Empagliflozin ranged from 98.60% to 100.12%, Linagliptin's accuracy ranged from 99.62% to 99.90%. It was discovered that every system suitability parameter fell between reasonable bounds.

This method is efficient, rapid, as well as suitable for use in (QCL) quality control laboratories to analyze Linagliptin and empagliflozin in solid dosage forms for pharmaceuticals.

Abstract 95 | PDF Downloads 32


1. G. Chawla, K. K. Chaudhary. “A complete review of empagliflozin: Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus” Diabetes. Met. Synd. Clin. Res. Rev, 13(3), 2001-2008.(2019).
2. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36(4):1033–1046.
3. Food and Drug Administration. FDA approves Jardiance to treat type-2 diabetes. August 1, 2014. Available at: http:// www.fda.gov/newsevents/newsroom/ pressannouncements/ucm407637.htm. Accessed August 17, 2014.
4. Metformin prescribing information. Baltimore, Maryland: Lupin Pharmaceuticals, Inc.; 2011.
5. Bakris GL, Fonseca VA, Sharma K, et al. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009;75(12):1272–1277
6. G. Chawla, K. K. Chaudhary. “A complete review of empagliflozin: Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus” Diabetes. Met. Synd. Clin. Res. Rev, 13(3), 2001-2008.(2019).
7. T.Ito, Y.Naito, N.Shimmoto, K.Ochiai, N.Hayashi, T.Okamura.“Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes final results of a 3-year post-marketing surveillance” Expert Opin Drug Saf., 20(3), 363-372.(2021).
8. T.Forst, A.Falk, G.Andersen,A. Fischer, M. M.Weber, S.Voswinkel, L. Plum‐Mörschel. “Effects on α-and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: A n exploratory mechanistic study” Diabetes ObesMetab., 19(4), 489-495. (2017).
9. T.Jojima, T.Tomotsune, T.Iijima, K.Akimoto, K.Suzuki, Y.Aso.“Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes” Diabetol. Metab.Syndr.., 8(1), 1-11.(2016).
10. Deacon, C. F., & Holst, J. J. (2010). Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.Expert opinion on investigational drugs, 19(1), 133-140.
11. B Ghatak, S., S Patel, D., Shanker, N., Srivastava, A., S Deshpande, S., & J Panchal, S. (2011). Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus. Current diabetes reviews, 7(5), 325-335.
12. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3- amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)- 3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J PharmacolExpTher 2008;325:175–82
13. Patil, S. D., Chaure, S. K., Rahman, M. A. H., Varpe, P. U., &Kshirsagar, S. (2017). Development and Validation of Simple UV-Spectrophotometric Method for the Determination of Empagliflozin. Asian J. Pharm. Ana, 7(1), 18-22.
14. Ayoub, B. M., &Mowaka, S. (2017). LC–MS/MS determination of empagliflozin and metformin. Journal of Chromatographic Science, 55(7), 742-747.
15. LakshmanaRao, A., Prasanthi, T., &Anusha, E. L. (2019). RP-HPLC method development and validation for simultaneous estimation of linagliptin and empagliflozin. Indian Drugs, 56, 68-71.

Most read articles by the same author(s)

1 2 > >>